ALK (G1269S)
Sign in to save this workspaceALK · Variant type: point · HGVS: p.G1269S
Drug response on this variant
| # | Drug | Inhibition on variant | Residual | KISS |
|---|---|---|---|---|
| 1 | Gilteritinib | 99.4% | 0.6% | 88.97 |
| 2 | Ceritinib | 98.8% | 1.2% | 95.44 |
| 3 | Brigatinib | 97.7% | 2.3% | 82.96 |
| 4 | Entrectinib | 97.5% | 2.5% | 93.69 |
| 5 | Alectinib | 97.4% | 2.6% | 95.49 |
| 6 | Lazertinib | 95.6% | 4.4% | 97.47 |
| 7 | Repotrectinib | 94.7% | 5.3% | 84.21 |
| 8 | Bosutinib | 93.6% | 6.4% | 87.22 |
| 9 | Crizotinib | 93.2% | 6.8% | 91.39 |
| 10 | Lorlatinib | 92.8% | 7.2% | 97.24 |
| 11 | Nintedanib | 82.1% | 17.9% | 90.23 |
| 12 | Sunitinib | 61.8% | 38.2% | 91.73 |
| 13 | Osimertinib | 58.4% | 41.6% | 97.24 |
| 14 | Fostamatinib | 49.8% | 50.2% | 96.74 |
| 15 | Darovasertib | 49.1% | 50.9% | 96.99 |
| 16 | Defactinib | 45.2% | 54.8% | 92.68 |
| 17 | Cabozantinib | 43.5% | 56.5% | 92.73 |
| 18 | Pacritinib | 43.3% | 56.7% | 88.64 |
| 19 | Neratinib | 41.8% | 58.2% | 93.18 |
| 20 | Pralsetinib | 39.7% | 60.3% | 93.43 |
| 21 | Alpelisib | 31.8% | 68.2% | 97.22 |
| 22 | Axitinib | 25.6% | 74.4% | 93.23 |
| 23 | Pazopanib | 23.2% | 76.8% | 97.49 |
| 24 | Selpercatinib | 15.8% | 84.2% | 96.72 |
| 25 | Trametinib | 15.2% | 84.8% | 99.50 |
Wild-type vs variant — drug response delta
Positive Δ means the drug hits the variant harder than wild-type (mutation-selective); negative Δ means it loses potency (resistance).
| Drug | Variant inh | WT inh | Δ (variant − WT) |
|---|---|---|---|
| Gilteritinib | 99.4% | 99.5% | -0.1% |
| Ceritinib | 98.8% | 98.3% | +0.5% |
| Brigatinib | 97.7% | 99.2% | -1.5% |
| Entrectinib | 97.5% | 98.8% | -1.3% |
| Alectinib | 97.4% | 98.6% | -1.1% |
| Lazertinib | 95.6% | 46.3% | +49.4% |
| Repotrectinib | 94.7% | 99.4% | -4.7% |
| Bosutinib | 93.6% | 75.1% | +18.5% |
| Crizotinib | 93.2% | 97.7% | -4.6% |
| Lorlatinib | 92.8% | 97.2% | -4.5% |
| Nintedanib | 82.1% | 84.9% | -2.8% |
| Sunitinib | 61.8% | 87.7% | -25.9% |
| Osimertinib | 58.4% | 80.5% | -22.1% |
| Fostamatinib | 49.8% | — | — |
| Darovasertib | 49.1% | — | — |
| Defactinib | 45.2% | — | — |
| Cabozantinib | 43.5% | — | — |
| Pacritinib | 43.3% | 55.3% | -12.0% |
| Neratinib | 41.8% | — | — |
| Pralsetinib | 39.7% | 82.6% | -42.8% |
| Alpelisib | 31.8% | 80.7% | -48.8% |
| Axitinib | 25.6% | — | — |
| Pazopanib | 23.2% | — | — |
| Selpercatinib | 15.8% | — | — |
| Trametinib | 15.2% | — | — |
Cancer associations
| Cancer | Organ | Source |
|---|---|---|
| carcinoma_lung | Lung | |
| anaplastic_large_cell_lymphoma | Blood/Lymphatic System |
Annotations
Sign in to read and post annotations.
Loading…
Served from saifudeen2026@1.0.0 · API 0.1.0 · 11.7ms